Ritter Pharmaceuticals Announces Phase 3 Plans after its End of Phase 2 Meeting with FDA on RP-G28 for Lactose Intolerance

Company has incorporated guidance from FDA on key elements of its Phase 3 program to support a New Drug Application (NDA) for RP-G28 Los Angeles, California, August 18, 2017 – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (the “Company”), a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced its […]

Leave Your Comments »

Ritter Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update

LOS ANGELES (August 7, 2017) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today reported financial results for the second quarter ended June 30, 2017. Recent Highlights Announced that the FDA has agreed to schedule […]

Leave Your Comments »

Ritter Pharmaceuticals Reports Further Analysis from its Phase 2b/3 Trial Results Demonstrating Significant Reductions in Lactose Intolerance Symptoms

Analysis shows clinically meaningful benefit from symptoms, global patient-reported and real-world assessments Los Angeles, California, August 3, 2017 – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (the “Company”), a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases today announced additional findings and data analysis from its Phase 2b/3 study designed to evaluate […]

Leave Your Comments »

Ritter Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Updates

LOS ANGELES (May 9, 2017) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today reported financial results for the first quarter ended March 31, 2017 and provided other business updates. Recent Highlights Clinical microbiome data […]

Leave Your Comments »

Ritter Pharmaceuticals Announces Issuance of New Patents for its Lactose Intolerance Treatment, RP-G28, and Provides an Update on its Path Forward into Phase 3

LOS ANGELES (May 2, 2017) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it has been issued three new patents directed to its development compound RP-G28.  The Company is also providing an […]

Leave Your Comments »

Ritter Pharmaceuticals, Inc. Announces End of Phase 2 Meeting with the FDA and Initiates Phase 3 Program Development Activities

Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (the “Company”) today, April 12, 2017, announced that the U.S. Food and Drug Administration (FDA) has agreed to schedule an end of phase 2 meeting with the company which is expected to take place in the third quarter of 2017. The Company plans to discuss the results of its recently […]

Leave Your Comments »

Ritter Pharmaceuticals Announces Lactose Intolerance Treatment, RP-G28, Demonstrated Efficacy and Clinically Meaningful Benefit in Phase 2b/3 Clinical Trial

Los Angeles, California, March 28, 2017 – Ritter Pharmaceuticals, Inc. (the “Company”) today announced topline findings from its Phase 2b/3 study designed to evaluate RP-G28 in subjects with lactose intolerance. Results from the 377-subject trial show a clinically meaningful benefit to subjects in the reduction of lactose intolerance symptoms across a variety of outcome measures. The […]

Leave Your Comments »

Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update

LOS ANGELES (February 27, 2017) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today reported financial results for the fourth quarter and full year ended December 31, 2016. Recent Highlights Last patient dosing and all […]

Leave Your Comments »

Ritter Pharmaceuticals Announces Collaboration with University of British Columbia to Explore Development of Microbiome Therapeutics in Environmental Enteropathy

Ritter Pharmaceuticals Announces Collaboration with University of British Columbia to Explore Development of Microbiome Therapeutics in Environmental Enteropathy LOS ANGELES (February 13, 2017) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it is […]

Leave Your Comments »

Lactose Intolerance: It Means Business

Lactose Intolerance means just what it says…no fancy words, no fluff, just a straight shooter.  If you suffer from lactose intolerance you understand that this condition means business.  But for those of you lucky enough to not be included in the over 1 billion global population* that suffer from this condition, let me break it […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD